oncnursingnews12h
Bevacizumab’s Benefit in Colorectal Cancer May Be Limited to 2 Years Post-Administration
The 2-year benefit of bevacizumab in colorectal cancer may explain why survival benefits are seen in studies with two-year, ...
oncnursingnews15h
Aspirin Linked to Lower CRC Recurrence in Patients With PI3K Mutations
Aspirin reduced disease recurrence in patients PI3K-mutated colorectal cancer, underscoring the value of early genomic ...